Dipo, Tom Odera, Nashon Martini and Geoffrey Awesi for helping us in data collection. We thank Dr. John Vulule for the support he accorded us in carrying out this work. We are grateful to Dr. Stephen Munga for his critical review of the draft manuscript. Lastly, we are highly grateful to Dr. Steve Krause and Mr. Peter DeChant for their support. This work is published with permission from the Director of the Kenya Medical Research Institute.Author ContributionsConceived and designed the experiments: BAN JAS JPM AKG. Performed the experiments: BAN. Analyzed the data: BAN. Contributed reagents/ materials/analysis tools: BAN. Wrote the paper: BAN.
Cancer of the cervis is the third most common cancer affecting women worldwide. Cervical c is preventable but continues to cause the deaths of more than 270,000 women worldwide each year [1], of whom over 85 percent live in developing countries where existing programs to detect and provide timely treatment do not reach or are beyond the means of most women [1,2]. Each year in Peru, cancer of the cervix is responsible for the deaths of an estimated 2,098 women [1] and is the most common cause of mortality among women 25 to 44 years old [3]. Two strains of human papillomavirus (HPV), types 16 and 18, account for about 70 percent of cervical cancers [4], approximately 90 percent of anal cancers, and a smaller subset (,50 percent) of other cancers, e.g., oropharyngeal, penile, vaginal, and vulvar [5]. Vaccines against the two most common HPV types, 16 and 18, have proven safe and efficacious [6,7] in preventing precancerous lesions in HPV-naive girls and women. Prophylactic vaccination targeting these genotypes is expected to result in significant reductions in the burden of cervical cancer and otherPLOS ONE | www.plosone.orgcancers associated with these genotypes, provided that these vaccination programs can achieve significant coverage of the target population [8]. New order BAY1217389 vaccine adoption has taken more time in lower-resource settings: hepatitis B virus vaccine adoption in low-income countries took nearly 20 years, twice as long as in high-income countries [9]. Vaccine price is often a key factor in vaccine decision-making [10], though this may be less true for countries eligible for subsidized vaccine through the GAVI Alliance. Prior to widespread HPV vaccine introduction, speculation about potential significant adoption barriers focused on several issues: the target age group was outside the routine GS-5816 supplier infant immunization schedule, the vaccine was for girls only, the vaccine protected against a sexually transmitted virus, and the benefits of vaccination were long term rather than immediate [11,12]. Peru’s Ministry of Health implemented an HPV vaccine demonstration project to study the issues necessary to make informed decisions about the introduction of the vaccine into the national immunization strategy. This project implemented HPV vaccination in 2008 to girls aged nine years or older inParental Acceptance of HPV Vaccine in Perugrade 5 of state and private primary schools in a predefined area of the region of Piura that included rural, urban, and periurban locations. The project used existing health and education systems and structures at local and regional levels for community sensitization and mobilization, vaccine administration, delivery, and cold chain maintenance, and monitoring and supervision [13]. The immunization program in Peru is well established and nearly universally recognized at the com.Dipo, Tom Odera, Nashon Martini and Geoffrey Awesi for helping us in data collection. We thank Dr. John Vulule for the support he accorded us in carrying out this work. We are grateful to Dr. Stephen Munga for his critical review of the draft manuscript. Lastly, we are highly grateful to Dr. Steve Krause and Mr. Peter DeChant for their support. This work is published with permission from the Director of the Kenya Medical Research Institute.Author ContributionsConceived and designed the experiments: BAN JAS JPM AKG. Performed the experiments: BAN. Analyzed the data: BAN. Contributed reagents/ materials/analysis tools: BAN. Wrote the paper: BAN.
Cancer of the cervis is the third most common cancer affecting women worldwide. Cervical c is preventable but continues to cause the deaths of more than 270,000 women worldwide each year [1], of whom over 85 percent live in developing countries where existing programs to detect and provide timely treatment do not reach or are beyond the means of most women [1,2]. Each year in Peru, cancer of the cervix is responsible for the deaths of an estimated 2,098 women [1] and is the most common cause of mortality among women 25 to 44 years old [3]. Two strains of human papillomavirus (HPV), types 16 and 18, account for about 70 percent of cervical cancers [4], approximately 90 percent of anal cancers, and a smaller subset (,50 percent) of other cancers, e.g., oropharyngeal, penile, vaginal, and vulvar [5]. Vaccines against the two most common HPV types, 16 and 18, have proven safe and efficacious [6,7] in preventing precancerous lesions in HPV-naive girls and women. Prophylactic vaccination targeting these genotypes is expected to result in significant reductions in the burden of cervical cancer and otherPLOS ONE | www.plosone.orgcancers associated with these genotypes, provided that these vaccination programs can achieve significant coverage of the target population [8]. New vaccine adoption has taken more time in lower-resource settings: hepatitis B virus vaccine adoption in low-income countries took nearly 20 years, twice as long as in high-income countries [9]. Vaccine price is often a key factor in vaccine decision-making [10], though this may be less true for countries eligible for subsidized vaccine through the GAVI Alliance. Prior to widespread HPV vaccine introduction, speculation about potential significant adoption barriers focused on several issues: the target age group was outside the routine infant immunization schedule, the vaccine was for girls only, the vaccine protected against a sexually transmitted virus, and the benefits of vaccination were long term rather than immediate [11,12]. Peru’s Ministry of Health implemented an HPV vaccine demonstration project to study the issues necessary to make informed decisions about the introduction of the vaccine into the national immunization strategy. This project implemented HPV vaccination in 2008 to girls aged nine years or older inParental Acceptance of HPV Vaccine in Perugrade 5 of state and private primary schools in a predefined area of the region of Piura that included rural, urban, and periurban locations. The project used existing health and education systems and structures at local and regional levels for community sensitization and mobilization, vaccine administration, delivery, and cold chain maintenance, and monitoring and supervision [13]. The immunization program in Peru is well established and nearly universally recognized at the com.